	US 11,890,353 B2
	Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies
Evan A. Scott, Northfield, IL (US); Guillermo A. Ameer, Chicago, IL (US); Jacqueline A. Burke, Chicago, IL (US); and Helena Freire Haddad, Evanston, IL (US)
Assigned to Northwestern University, Evanston, IL (US)
Filed by NORTHWESTERN UNIVERSITY, Evanston, IL (US)
Filed on Oct. 15, 2020, as Appl. No. 17/071,653.
Claims priority of provisional application 62/915,608, filed on Oct. 15, 2019.
Prior Publication US 2021/0106697 A1, Apr. 15, 2021
Int. Cl. A61K 49/00 (2006.01); A01K 67/027 (2006.01)

CPC A61K 49/0008 (2013.01) [A01K 67/027 (2013.01); A01K 2207/10 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01)]

19 Claims

1. A method of making an in vivo model for detecting and monitoring anti-poly(ethylene glycol) (PEG) antibodies and an immune response to antigens recognized by the anti-PEG antibodies, the method comprising:

(a) administering subcutaneously to an animal model a composition comprising at least one commercially available antibody against poly(ethylene glycol) chains with a molecular weight of at least 550 Da, wherein the at least one commercially available antibody is selected from antibody clone 1D9-6, antibody clone 5E10E9, antibody clone 5D6-3, and antibody clone 09F02; and

(b) detecting anti-PEG antibodies within the animal model at a level of at least 44 ng/ml.